CK-136 / Cytokinetics - LARVOL DELTA

A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=57 | Terminated | Sponsor: Cytokinetics | Recruiting ➔ Terminated; Terminated early per sponsor decision.

Trial termination

Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility. (PubMed, J Med Chem) - "In vivo echocardiography assessment of the optimized leads showed concentration dependent increases in fractional shortening and an improved pharmacodynamic window compared to myosin activator CK-138. Overall, nelutroctiv was found to possess the desired selectivity, a favorable pharmacodynamic window relative to myosin activators, and a preclinical PK profile to support clinical development."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=78 | Recruiting | Sponsor: Cytokinetics | Trial completion date: Sep 2023 ➔ Jan 2024 | Trial primary completion date: Aug 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date

Modulation of muscle contractility: The design of novel therapeutics for cardiovascular disease (ACS-Sp 2023) - "The lecture will focus on the discovery of three separate small molecules that directly modulate contractility at the cardiac sarcomere in attempts to normalize the underlying dysfunction. Omecamtiv mecarbil is a selective cardiac myosin activator that increases cardiac performance and improves outcomes in patients with HFrEF; CK-136 is a selective cardiac troponin activator intended to address different types of heart failure; and aficamten is a selective cardiac myosin inhibitor designed to treat patients with HCM by restoring the proper degree of contractility within the sarcomere."

Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertrophic Cardiomyopathy

A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=78 | Recruiting | Sponsor: Cytokinetics

New P1 trial

Small Molecules acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases. (PubMed, Int J Mol Sci) - "Omecamtiv Mecarbil and Danicamtiv (myosin activators), Mavacamten, CK-274 and MYK-581 (myosin inhibitors) and AMG 594 (Ca-sensitiser) are all small molecules that allosterically modulate troponin or myosin. A novel category of small molecules known as "recouplers" was reported to target a phenomenon termed uncoupling commonly found in familial cardiomyopathies but has not progressed beyond preclinical work. In conclusion, the contractile apparatus is a promising target for new drug development."

Journal • Review • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

"$CYTK Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 From Amgen https://t.co/4vKc1sfznV" (@stock_titan)